시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 인간 융모성 성선자극호르몬 시장 보고서(2025년)
Human Chorionic Gonadotropin Global Market Report 2025
상품코드 : 1825764
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,482,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,370,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,257,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

인간 융모성 성선자극호르몬 시장 규모는 향후 몇 년 동안 강력한 성장이 예상됩니다. 2029년에는 CAGR 8.2%로 14억 1,000만 달러로 성장할 것입니다. 예측 기간의 성장은 불임 발생률 증가, 다낭성난소증후군의 급증, 여성 불임의 증가, 동물 의학에서 HCG 사용량 증가에 기인합니다. 예측 기간의 주요 동향으로는 임신 감지 기술의 발전, 혁신적인 약물 처방, 기술 통합, R&D 집중, 제품 혁신 등을 꼽을 수 있습니다.

향후 5년간 8.2%의 성장률 전망은 지난번 전망치보다 0.2% 소폭 하락한 수치입니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향에 기인합니다. 관세 장벽은 스위스나 덴마크에서 공급되는 인간 융모성 성선자극호르몬(hCG) 호르몬 요법의 비용을 상승시킴으로써 미국 시장을 저해하고 불임 치료를 지연시키며 생식 내분비학 비용을 상승시킬 것으로 예상됩니다. 또한, 상호 관세와 무역 긴장과 제한의 증가로 인한 세계 경제와 무역에 대한 악영향으로 인해 그 영향은 더욱 광범위하게 나타날 것으로 보입니다.

불임의 증가율은 향후 몇 년 동안 인간 융모성 성선자극호르몬(hCG) 시장의 성장을 촉진할 것으로 예상됩니다. 불임은 최소 1년 이상 피임 없이 성관계를 지속해도 임신이 되지 않는 상태로 정의되며, 증가 추세에 있습니다. 그 요인으로는 출산 지연, 생활습관 변화, 환경 노출, 병력 등을 들 수 있습니다. 인간 융모성 성선자극호르몬(hCG)은 불임 치료에서 여성의 배란을 자극하고, 남성의 테스토스테론 생산을 지원하며, 난자 방출을 촉진하고 불임 치료 결과를 개선하는 데 활용되고 있습니다. 예를 들어, 2023년 4월 세계보건기구(WHO)는 불임이 성인 인구의 약 17.5%, 즉 전 세계 약 6명 중 1명꼴로 발병하고 있다고 보고하며, 접근성이 좋고 질 높은 불임 치료가 시급하다고 강조했습니다. 그 결과, 불임률의 증가가 인간 융모성 성선자극호르몬 시장의 성장을 주도하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별·국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

제31장 기타 주요 기업과 혁신적 기업

제32장 세계의 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병

제34장 최근의 시장 동향

제35장 시장 잠재력이 높은 국가, 부문, 전략

제36장 부록

KSM
영문 목차

영문목차

Human chorionic gonadotropin (hCG) is a hormone produced during pregnancy by the placenta shortly after embryo implantation in the uterus. It is essential for sustaining pregnancy by stimulating the corpus luteum in the ovary to produce progesterone, which maintains the uterine lining and prevents its breakdown.

The primary technologies for producing hCG are natural source extraction and recombinant technology. Recombinant technology involves combining DNA fragments from various organisms to create new genetic combinations. hCG is used in treating female infertility, oligospermia, male hypogonadism, and other conditions. It is distributed through hospital pharmacies, retail pharmacies, and online pharmacies, and is utilized by fertility clinics, research institutions, and other users.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The human chorionic gonadotropin market research report is one of a series of new reports from The Business Research Company that provides human chorionic gonadotropin market statistics, including human chorionic gonadotropin industry global market size, regional shares, competitors with a human chorionic gonadotropin market share, detailed human chorionic gonadotropin market segments, market trends, and opportunities, and any further data you may need to thrive in the human chorionic gonadotropin industry. This human chorionic gonadotropin market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The human chorionic gonadotropin market size has grown strongly in recent years. It will grow from $0.95 billion in 2024 to $1.02 billion in 2025 at a compound annual growth rate (CAGR) of 8.4%. The growth in the historic period can be attributed to the rise in the prevalence of hypogonadism in the geriatric population, increase in awareness toward HCG among healthcare professionals and patients, rise in popularity of fertility tourism, increase in the geriatric population, and increase in affordability and improvement in healthcare facilities.

The human chorionic gonadotropin market size is expected to see strong growth in the next few years. It will grow to $1.41 billion in 2029 at a compound annual growth rate (CAGR) of 8.2%. The growth in the forecast period can be attributed to the increasing incidence of infertility, surging prevalence of polycystic ovary syndrome, increasing female infertility, and rising usage of HCG in veterinary medicine. Major trends in the forecast period include advancements in pregnancy detection, innovative drug formulations, technological integration, focus on research and development, and product innovation.

The forecast of 8.2% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff barriers are expected to hamper the U.S. market by increasing the cost of Human Chorionic Gonadotropin(hCG) hormone therapies sourced from Switzerland and Denmark, thereby delaying fertility treatments and elevating reproductive endocrinology costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

An increasing rate of infertility is anticipated to propel the growth of the human chorionic gonadotropin (hCG) market in the coming years. Infertility, defined as the inability to conceive after at least one year of consistent, unprotected intercourse, is on the rise. Contributing factors include delayed childbearing, lifestyle changes, environmental exposures, and medical conditions. Human chorionic gonadotropin (hCG) is utilized in infertility treatments to stimulate ovulation in women and support testosterone production in men, facilitating egg release and improving fertility outcomes. For instance, in April 2023, the World Health Organization reported that infertility affects approximately 17.5% of the adult population, or roughly one in six people globally, underscoring the urgent need for accessible, high-quality fertility care. Consequently, the rising infertility rate is driving the growth of the human chorionic gonadotropin market.

Key players in the human chorionic gonadotropin market are focusing on the development of innovative products, such as pregnancy detection kits, to enhance diagnostic accuracy, improve patient outcomes, and broaden market reach. Pregnancy detection kits are designed to confirm pregnancy by detecting human chorionic gonadotropin (hCG) in the body. For example, in June 2022, Proov, a US-based medical equipment manufacturer, introduced new hCG tests for early pregnancy detection, enabling women to verify pregnancy up to six days before their expected period. These tests identify hCG in urine with a reliability rate exceeding 99%, providing a dependable and accessible method for women to monitor their pregnancy status earlier than traditional tests and make informed reproductive health decisions.

In September 2023, Lupin Limited, an India-based pharmaceutical company, acquired five brands from Menarini for an undisclosed sum. This acquisition aims to expand Lupin's portfolio and strengthen its position in key therapeutic areas by integrating five established brands from Menarini. Menarini Group, an Italy-based pharmaceutical and diagnostics company, offers services related to human chorionic gonadotropin (hCG).

Major companies operating in the human chorionic gonadotropin market are Pfizer Inc., Merck & Co Inc., Novartis AG, Bristol-Myers Squibb Company, Fresenius Kabi AG, Janssen Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, Sun Pharmaceutical Industries Limited, Menarini Group, Cipla Limited, Hikma Pharmaceuticals plc, Ferring Pharmaceuticals Inc., Intas Pharmaceuticals Ltd., Zydus Lifesciences Limited, Lupin Limited, Shenzhen Hepalink Pharmaceutical Group Co. Ltd., Scripps Laboratories Inc., Aspen Pharmacare Holdings Limited, Corona Remedies Pvt Ltd., Sanzyme Private Limited, Biocare Medical LLC, Lee BioSolutions Inc., MyBioSource Inc.

North America was the largest region in the human chorionic gonadotropin market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the human chorionic gonadotropin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the human chorionic gonadotropin market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The human chorionic gonadotropin market includes revenues earned by entities by providing services such as fertility treatments, hormone level monitoring, assisted reproductive technologies (ART), and pregnancy testing. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Human Chorionic Gonadotropin Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on human chorionic gonadotropin market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for human chorionic gonadotropin ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The human chorionic gonadotropin market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Human Chorionic Gonadotropin Market Characteristics

3. Human Chorionic Gonadotropin Market Trends And Strategies

4. Human Chorionic Gonadotropin Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Human Chorionic Gonadotropin Growth Analysis And Strategic Analysis Framework

6. Human Chorionic Gonadotropin Market Segmentation

7. Human Chorionic Gonadotropin Market Regional And Country Analysis

8. Asia-Pacific Human Chorionic Gonadotropin Market

9. China Human Chorionic Gonadotropin Market

10. India Human Chorionic Gonadotropin Market

11. Japan Human Chorionic Gonadotropin Market

12. Australia Human Chorionic Gonadotropin Market

13. Indonesia Human Chorionic Gonadotropin Market

14. South Korea Human Chorionic Gonadotropin Market

15. Western Europe Human Chorionic Gonadotropin Market

16. UK Human Chorionic Gonadotropin Market

17. Germany Human Chorionic Gonadotropin Market

18. France Human Chorionic Gonadotropin Market

19. Italy Human Chorionic Gonadotropin Market

20. Spain Human Chorionic Gonadotropin Market

21. Eastern Europe Human Chorionic Gonadotropin Market

22. Russia Human Chorionic Gonadotropin Market

23. North America Human Chorionic Gonadotropin Market

24. USA Human Chorionic Gonadotropin Market

25. Canada Human Chorionic Gonadotropin Market

26. South America Human Chorionic Gonadotropin Market

27. Brazil Human Chorionic Gonadotropin Market

28. Middle East Human Chorionic Gonadotropin Market

29. Africa Human Chorionic Gonadotropin Market

30. Human Chorionic Gonadotropin Market Competitive Landscape And Company Profiles

31. Human Chorionic Gonadotropin Market Other Major And Innovative Companies

32. Global Human Chorionic Gonadotropin Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Human Chorionic Gonadotropin Market

34. Recent Developments In The Human Chorionic Gonadotropin Market

35. Human Chorionic Gonadotropin Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기